Vivace Therapeutics Overview
Latest Deal Type
Series B
Vivace Therapeutics General Information
Description
Developer of a small molecule drug discovery and development firm intended to bring novel therapies to treat cancer patients. The company's firm is built on innovative science in novel pathways and leverages research from leading academic laboratories by developing therapeutics that could work alone or in combination with other drugs, enabling patients to conquer cancer.
Want to dig into this profile?
We’ll help you find what you need
Learn more
Vivace Therapeutics Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 2. Early Stage VC (Series B) |
28-Jun-2017 |
$25M |
0000 |
0000 |
Completed |
Startup |
| 1. Early Stage VC (Series A) |
20-Jan-2015 |
0000 |
0000 |
0000 |
Completed |
Startup |
Vivace Therapeutics Cap Table
To view Vivace Therapeutics‘s complete cap table, request access >>
| Stock |
# of Shares
Authorized |
Par Value |
Dividend Rate ($) |
Original
Issue Price |
Liquidation |
Liquidation
Pref. Multiple |
Conversion Price |
% Owned |
| Series B |
00,000,000 |
00.000000 |
00.00 |
00.00 |
00.00 |
00 |
00.00 |
00.000 |
| Series A |
00,000,000 |
00.000000 |
00.00 |
00 |
00 |
00 |
00 |
00.000 |
Vivace Therapeutics Competitors (33)
| Company Name |
Financing Status |
Location |
Employees |
Total Raised |
Last Financing Date/Type |
Last Financing
Amount |
| Imara |
Formerly VC-backed |
Boston, MA |
00 |
00000 |
00000000 |
00000 |
| 000000 00000000000 |
Formerly VC-backed |
South San Francisco, CA |
000 |
00000 |
000000 - 000 |
00000 |
| 000 0000000000000 |
Venture Capital-Backed |
Chester, United Kingdom |
00 |
000.00 |
00000000000 |
000.00 |
| 000000 00000000000 |
Corporation |
PA |
000 |
000.00 |
00000000 |
000.00 |
| 00000000 |
Venture Capital-Backed |
Tübingen, Germany |
000 |
00000 |
000000000000 |
00000 |
Vivace Therapeutics Executive Team (7)
| Name |
Title |
Board Seat |
Contact Info |
| Sofie Qiao Ph.D |
President, Chief Executive Officer and Board Member |
|
|
| Bin Liu Ph.D |
Scientific Co-Founder |
|
|
| Andrei Konradi Ph.D |
Vice President & Head of Chemistry |
|
|
| Leonard Post Ph.D |
Chief Scientific Officer & Board Member |
|
|
| Kun-Liang Guan Ph.D |
Scientific Co-Founder |
|
|
2 Former Executives